Orphan Grant Awarded to ONC201 Myeloma Trial

Share this content:
The FDA has awarded an orphan grant to ONC201, a selective antagonist of DRD2, in a multiple myeloma clinical trial.
The FDA has awarded an orphan grant to ONC201, a selective antagonist of DRD2, in a multiple myeloma clinical trial.

The U.S. Food and Drug Administration has awarded an orphan grant to ONC201, a selective antagonist of DRD2, in a multiple myeloma clinical trial.1

ONC201 has demonstrated excellent anticancer activity in various preclinical models of refractory multiple myeloma, and it has shown manageable toxicity and early signals of efficacy in several cancer types, including non-Hodgkin lymphoma.

The orally bioavailable inhibitor of Akt and ERK has also exhibited a therapeutic pharmacokinetic profile and induction of pharmacodynamic markers.

ONC201 activates the integrated stress response (ISR) using unique triggers, leading to the upregulation of a host of proteins that induce apoptosis and inhibit cancer growth. Multiple myeloma cells are especially sensitive to ISR activation, which is also a key mechanism of action of proteasome inhibitors like bortezomib.

"While significant progress has been made in the field of multiple myeloma and the treatments have meaningfully improved, patients with resistant disease need additional options," said Bart Barlogie, MD, Director of Research of the Myeloma Program of the Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai in New York. "It is gratifying to see introductions of new classes of compounds, such as ONC201 that represents the first clinical stage drug of the imipridone family that offer disruptive approaches in how to tackle this challenging disease.”

RELATED: In Search of the Right Treatment Combinations for Multiple Myeloma

The grant awarded totals $1.7 million to support the development of ONC201 in patients with relapsed/refractory multiple myeloma in a phase 2 program.

Reference

  1. Oncoceutics awarded FDA orphan grant for ONC201 multiple myeloma trial. Oncoceutics website. http://oncoceutics.com/oncoceutics-awarded-fda-orphan-grant-for-onc201-multiple-myeloma-trial/. Updated August 16, 2016. Accessed August 17, 2016.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters